drugset

drugset / Trial / NCT03685591

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

NCT03685591 ↗

Phase 1 Terminated 49 enrolled Pfizer

Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.

Timeline

Start: 2018-10-04
Primary completion: 2022-03-30
Completion: 2022-03-30

Publications

Yap TA, Choudhury AD, Hamilton E, Rosen LS, Stratton KL, Gordon MS, Schaer D, Liu L, Zhang L, Mittapalli RK, Zhong W, Soman N, Tolcher AW. PF-06952229, a selective TGF-beta-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors. ESMO Open. 2024 Sep;9(9):103653. doi: 10.1016/j.esmoop.2024.103653. Epub 2024 Aug 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Enzalutamide	Other / unclassified	160 mg	Oral
Subject	PF-06952229	Small molecule	20 mg	Oral
Subject	PF-06952229	Small molecule	40 mg	Oral
Subject	PF-06952229	Small molecule	80 mg	Oral
Subject	PF-06952229	Small molecule	150 mg	Oral
Subject	PF-06952229	Small molecule	250 mg	Oral
Subject	PF-06952229	Small molecule	375 mg	Oral
Subject	PF-06952229	Small molecule	500 mg	Oral
Subject	PF-06952229	Small molecule	625 mg	Oral
Subject	PF-06952229	Small molecule	750 mg	Oral

Indications